- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04937543
Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (TRIVID)
May 30, 2022 updated by: UPECLIN HC FM Botucatu Unesp
Randomized, Open-label, Three Arms Study to Evaluate the Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources in Patients With ≥ 18 Years Old (TRIVID Study)
Introduction: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the new coronavirus, causes a disease called COVID-19 that can trigger aggressive inflammatory responses.
In this sense, inhaled corticosteroid therapy (IC) has shown some favorable results in controlling the worsening of the disease, given that it has effects on pulmonary inflammation and can be an intervention to be used in the mild manifestations of COVID-19 in order to prevent disease progression and severity.
Regarding the role of bronchodilators, studies have suggested that their combination with IC exerts synergistic therapeutic effects.
Objective: To determine the efficacy of inhaled therapy of beclomethasone/formoterol/glycopyrronium (BFG) (100/6/12.5mcg)
and/or beclomethasone HFA 250 mcg in preventing the use of healthcare resources in patients ≥ 18 years of age at 28 days compared to usual care.
Method: participants will be randomized according to a ratio of 1:1:1 into three groups: (Group 1) Standard of care + BFG two doses 2x/day; (Group 2) standard treatment + beclomethasone HFA two doses 2x/day and (Group 3) standard treatment.
After collecting the signed informed consent form, research participants will be treated for 28 days and, after two days, will undergo a spirometry test.
Therefore, the total duration of the study for a given participant will be up to 30 days.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Botucatu, São Paulo, Brazil, 18618687
- Hospital das Clínicas da Faculdade de Medicina de Botucatu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria: A research participant will be eligible to participate in this study if ALL of the following criteria are met:
- Adult men or women (≥ 18 years of age)
- PCR positive SarsCoV-2
- Symptomatic participants must have at least 1 of the following symptoms in the inclusion: fever or self-reported fever perception in the last 24 hours, headache, sore throat, dry cough, fatigue, chest pain or choking sensation (without associating to respiratory distress), myalgia, anosmia, ageusia or gastrointestinal symptoms with up to 10 days onset.
- Participants with arterial pulse oximetry (SpO2) saturation ≥ 92% in room air at inclusion.
Participants with the following hematological and biochemical laboratory parameters obtained in the period of 7 days before D0:
- Hemoglobin> 9.0 g / dL-1
- Absolute Neutrophil Count ≥ 1000 mm-³
- Platelets ≥ 100,000 mm-3
- Creatinine clearance ≥ 30 mL / min-1 using the Cockcroft-Gault formula
- Alkaline phosphatase <10 × upper limit of normal (LSN), AST (TGOS) and ALT (TGPS) <10 × LSN.
- Laboratory pregnancy test (Negative β-hCG).
- Participants must understand, sign and date the voluntary informed consent form in writing at the visit prior to any specific protocol procedure.
- Participants must be able and willing to comply with study visits and procedures, as per the protocol.
Exclusion Criteria:
Research participants who meet any of the following exclusion criteria will be excluded from the study:
- Participants with moderate or severe acute respiratory failure or needing non-invasive ventilation or oxygen, or with SpO2 <92% or tachypnea (respiratory rate ≥ 30 breaths / minute).
- Participants with pre-existing, severe and uncontrolled organ failure, which prevents participation in the study by the investigator's judgment (non-relevant cardiac disease)
- Participant diagnosed with previous asthma using inhaled or oral corticosteroids in the last four weeks.
- Participant with previous use, in the last ten days of randomization, of inhaled, oral or injectable corticosteroids.
- Participant with previous diagnosis of chronic obstructive pulmonary disease, even if he is not using any inhaled medication.
- Pregnant or lactating women.
- Use of any product under investigation or unregistered within 3 months or within 5 half-lives before baseline, whichever is longer.
- Hypersensitivity to the drug and / or its excipients.
- Any condition that, in the investigator's opinion, could compromise the participant's safety or his adherence to the study protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No intervation
patients receiving standart of care
|
|
Active Comparator: Experimental intervation one
patients receiving standart of care + inhaled beclometasone
|
Adding belcamethasone to standard of care for Covid 19 positive patients
|
Active Comparator: Experimental intervation two
patients receiving standart of care + inhaled beclometasone/ formoterol / glycopyrronium
|
Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients in preventing the use of health resources in patients
Time Frame: 28 days after treatment
|
28 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Airway obstruction
Time Frame: 28 days after treatment
|
Spirometry
|
28 days after treatment
|
Small airway obstruction
Time Frame: 28 days after treatment
|
computadorized tomography
|
28 days after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Actual)
October 30, 2021
Study Completion (Anticipated)
May 20, 2022
Study Registration Dates
First Submitted
June 23, 2021
First Submitted That Met QC Criteria
June 23, 2021
First Posted (Actual)
June 24, 2021
Study Record Updates
Last Update Posted (Actual)
June 1, 2022
Last Update Submitted That Met QC Criteria
May 30, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Beclomethasone
- Glycopyrrolate
- Formoterol Fumarate
Other Study ID Numbers
- TRIV001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
Clinical Trials on inhaled beclametasone
-
Synspira, Inc.TerminatedLung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditionsUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveCzechia, Hungary
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveHungary, Slovakia
-
Galecto Biotech ABCompletedIdiopathic Pulmonary FibrosisUnited Kingdom
-
GlaxoSmithKlineCompletedCoughUnited Kingdom
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveSpain
-
Pearl Therapeutics, Inc.Completed
-
Liquidia Technologies, Inc.Nuventra, Inc.CompletedPrimary Pulmonary HypertensionUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma
-
Liquidia Technologies, Inc.Nuventra, Inc.Active, not recruitingPrimary Pulmonary HypertensionUnited States